[
  {
    "ts": "2025-12-31T13:39:13+00:00",
    "headline": "Dow Jones Industrials 2025: These Three Unexpected Stocks Top Nvidia",
    "summary": "The Dow Jones' top five stocks of the year included two names investors may not have expected to find next to AI giants like Nvidia and IBM.",
    "url": "https://www.investors.com/news/dow-jones-nvidia-ibm-goldman-sachs-caterpillar-johnson-stock-maket/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "35bf1efa-bea7-3401-aa27-bf3201623efe",
      "content": {
        "id": "35bf1efa-bea7-3401-aa27-bf3201623efe",
        "contentType": "STORY",
        "title": "Dow Jones Industrials 2025: These Three Unexpected Stocks Top Nvidia",
        "description": "",
        "summary": "The Dow Jones' top five stocks of the year included two names investors may not have expected to find next to AI giants like Nvidia and IBM.",
        "pubDate": "2025-12-31T13:39:13Z",
        "displayTime": "2025-12-31T13:39:13Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/35bf1efa-bea7-3401-aa27-bf3201623efe/dow-jones-industrials-2025-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/5d37fe135c49bb3a9d4c2c47901b590f",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zcW7r97lQijhddjb01igfw--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/5d37fe135c49bb3a9d4c2c47901b590f.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ycqTsZLKRPn60DrIFsM8Hg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/5d37fe135c49bb3a9d4c2c47901b590f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/dow-jones-nvidia-ibm-goldman-sachs-caterpillar-johnson-stock-maket/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "IBM"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "CAT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-31T12:21:00+00:00",
    "headline": "How Is Boston Scientific's Cardiovascular Growth Path Shaping Up?",
    "summary": "BSX's $50B cardiovascular business aims to outpace market growth across EP, WATCHMAN, ICTx and more.",
    "url": "https://finance.yahoo.com/news/boston-scientifics-cardiovascular-growth-path-122100422.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "54040519-766a-32a0-bd8b-783812bd9f57",
      "content": {
        "id": "54040519-766a-32a0-bd8b-783812bd9f57",
        "contentType": "STORY",
        "title": "How Is Boston Scientific's Cardiovascular Growth Path Shaping Up?",
        "description": "",
        "summary": "BSX's $50B cardiovascular business aims to outpace market growth across EP, WATCHMAN, ICTx and more.",
        "pubDate": "2025-12-31T12:21:00Z",
        "displayTime": "2025-12-31T12:21:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TNBAnrhWOnvvvNSvMEIuFg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rP7ZEHNft_Sb_FB9M.3i3w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/boston-scientifics-cardiovascular-growth-path-122100422.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/boston-scientifics-cardiovascular-growth-path-122100422.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BSX"
            },
            {
              "symbol": "MDT"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-31T14:34:42+00:00",
    "headline": "Pfizer, GSK Lead U.S. Drugmakers Planning 2026 Price Hikes on 350 Drugs",
    "summary": "List prices to rise an average of 4% despite federal pressure to curb costs.",
    "url": "https://finance.yahoo.com/news/pfizer-gsk-lead-u-drugmakers-143442942.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "60f9e371-cf5c-34d8-8971-8c8928c120be",
      "content": {
        "id": "60f9e371-cf5c-34d8-8971-8c8928c120be",
        "contentType": "STORY",
        "title": "Pfizer, GSK Lead U.S. Drugmakers Planning 2026 Price Hikes on 350 Drugs",
        "description": "",
        "summary": "List prices to rise an average of 4% despite federal pressure to curb costs.",
        "pubDate": "2025-12-31T14:34:42Z",
        "displayTime": "2025-12-31T14:34:42Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/08081c8c254eb269c81ba8feeb03a4b4",
          "originalWidth": 500,
          "originalHeight": 500,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vu.kxzmN7yCA.wz8Cs.cHg--~B/aD01MDA7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/08081c8c254eb269c81ba8feeb03a4b4.cf.webp",
              "width": 500,
              "height": 500,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Brb0J12XOUXl4lathAg3vw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/08081c8c254eb269c81ba8feeb03a4b4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-gsk-lead-u-drugmakers-143442942.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-gsk-lead-u-drugmakers-143442942.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "GLAXF"
            },
            {
              "symbol": "GSK"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-31T13:10:00+00:00",
    "headline": "BAYRY's 2025 Revival: Will the Momentum Continue in 2026?",
    "summary": "BAYRY shares have risen 121.6% in a year as new FDA approvals, pipeline wins and litigation updates fuel a sharp turnaround.",
    "url": "https://finance.yahoo.com/news/bayrys-2025-revival-momentum-continue-131000852.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "6c9b4af2-32e3-3510-aec4-a2ddcc852ed9",
      "content": {
        "id": "6c9b4af2-32e3-3510-aec4-a2ddcc852ed9",
        "contentType": "STORY",
        "title": "BAYRY's 2025 Revival: Will the Momentum Continue in 2026?",
        "description": "",
        "summary": "BAYRY shares have risen 121.6% in a year as new FDA approvals, pipeline wins and litigation updates fuel a sharp turnaround.",
        "pubDate": "2025-12-31T13:10:00Z",
        "displayTime": "2025-12-31T13:10:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/50c06d1d19c16cb71d6cb49028119372",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5pnU3NQ.800lSpcRBKjZNg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/50c06d1d19c16cb71d6cb49028119372.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/W2_ZZ2Pl7OVNL4tXoICDoQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/50c06d1d19c16cb71d6cb49028119372.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bayrys-2025-revival-momentum-continue-131000852.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bayrys-2025-revival-momentum-continue-131000852.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "BAYZF"
            },
            {
              "symbol": "BAYRY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-31T16:12:45+00:00",
    "headline": "AbbVie (ABBV) Maintains Immunology Dominance as Analysts Downplay Competitive Threat From J&J’s Tremfya to Skyrizi Market Share",
    "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best stocks for the next decade. On December 12, Morgan Stanley raised the firm’s price target on AbbVie to $269 from $261 with an Overweight rating on the shares. Earlier on December 10, HSBC upgraded AbbVie to Buy from Hold with a price target of $265, which was […]",
    "url": "https://finance.yahoo.com/news/abbvie-abbv-maintains-immunology-dominance-161245809.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "228dd1ca-30f8-38c8-be04-a386522e2179",
      "content": {
        "id": "228dd1ca-30f8-38c8-be04-a386522e2179",
        "contentType": "STORY",
        "title": "AbbVie (ABBV) Maintains Immunology Dominance as Analysts Downplay Competitive Threat From J&J’s Tremfya to Skyrizi Market Share",
        "description": "",
        "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best stocks for the next decade. On December 12, Morgan Stanley raised the firm’s price target on AbbVie to $269 from $261 with an Overweight rating on the shares. Earlier on December 10, HSBC upgraded AbbVie to Buy from Hold with a price target of $265, which was […]",
        "pubDate": "2025-12-31T16:12:45Z",
        "displayTime": "2025-12-31T16:12:45Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/c554ad8e2af773e2e2a8438bfe2291ee",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "AbbVie (ABBV) Maintains Immunology Dominance as Analysts Downplay Competitive Threat From J&J’s Tremfya to Skyrizi Market Share",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aXAa28AvezyRv056g_RUEg--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/c554ad8e2af773e2e2a8438bfe2291ee.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lzVMSqWRbEKelBHS4c050A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/c554ad8e2af773e2e2a8438bfe2291ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-abbv-maintains-immunology-dominance-161245809.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-abbv-maintains-immunology-dominance-161245809.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-31T14:30:02+00:00",
    "headline": "Wall Street Analysts Think Johnson & Johnson (JNJ) Is a Good Investment: Is It?",
    "summary": "The average brokerage recommendation (ABR) for Johnson & Johnson (JNJ) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
    "url": "https://finance.yahoo.com/news/wall-street-analysts-think-johnson-143002956.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "2bd58859-4d19-3346-ab27-73e144f3a434",
      "content": {
        "id": "2bd58859-4d19-3346-ab27-73e144f3a434",
        "contentType": "STORY",
        "title": "Wall Street Analysts Think Johnson & Johnson (JNJ) Is a Good Investment: Is It?",
        "description": "",
        "summary": "The average brokerage recommendation (ABR) for Johnson & Johnson (JNJ) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
        "pubDate": "2025-12-31T14:30:02Z",
        "displayTime": "2025-12-31T14:30:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/5ecaf2a9bf082a5f3a554e6526b34be0",
          "originalWidth": 900,
          "originalHeight": 601,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/R44DoTZV_0PRYb38xOZB.w--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5ecaf2a9bf082a5f3a554e6526b34be0.cf.webp",
              "width": 900,
              "height": 601,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/XH9RX1D8m2SgxOWLNEKDKQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5ecaf2a9bf082a5f3a554e6526b34be0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/wall-street-analysts-think-johnson-143002956.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/wall-street-analysts-think-johnson-143002956.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-31T14:00:07+00:00",
    "headline": "Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock",
    "summary": "Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finance.yahoo.com/news/know-beyond-why-johnson-johnson-140007370.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "7b9cb457-76c7-3b65-9cdc-c2e9705cf698",
      "content": {
        "id": "7b9cb457-76c7-3b65-9cdc-c2e9705cf698",
        "contentType": "STORY",
        "title": "Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock",
        "description": "",
        "summary": "Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
        "pubDate": "2025-12-31T14:00:07Z",
        "displayTime": "2025-12-31T14:00:07Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/3d7c5b2146ac04ffd51752e17ff2a619",
          "originalWidth": 900,
          "originalHeight": 506,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WMc9TPUzGnRwQQgeGPg3VQ--~B/aD01MDY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3d7c5b2146ac04ffd51752e17ff2a619.cf.webp",
              "width": 900,
              "height": 506,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kbEpsaBWvOchoGFZ2uOESQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3d7c5b2146ac04ffd51752e17ff2a619.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/know-beyond-why-johnson-johnson-140007370.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/know-beyond-why-johnson-johnson-140007370.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-31T16:41:49+00:00",
    "headline": "Here’s What Analysts Think About Halozyme Therapeutics (HALO)",
    "summary": "Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best affordable stocks with good earnings growth for 2026. Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced on December 18 that Johnson & Johnson received approval from the U.S. Food and Drug Administration (FDA) for RYBREVANT FASPRO, co-formulated with ENHANZE® for people with epidermal growth factor receptor (EGFR)-mutated locally advanced or […]",
    "url": "https://finance.yahoo.com/news/analysts-think-halozyme-therapeutics-halo-164149905.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "1d335d85-cf10-36ef-a1b6-0fc3567e3a6a",
      "content": {
        "id": "1d335d85-cf10-36ef-a1b6-0fc3567e3a6a",
        "contentType": "STORY",
        "title": "Here’s What Analysts Think About Halozyme Therapeutics (HALO)",
        "description": "",
        "summary": "Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best affordable stocks with good earnings growth for 2026. Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced on December 18 that Johnson & Johnson received approval from the U.S. Food and Drug Administration (FDA) for RYBREVANT FASPRO, co-formulated with ENHANZE® for people with epidermal growth factor receptor (EGFR)-mutated locally advanced or […]",
        "pubDate": "2025-12-31T16:41:49Z",
        "displayTime": "2025-12-31T16:41:49Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/7b0524267df57743748c8c566f6ab6ea",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Is Halozyme Therapeutics, Inc. (HALO) the Unstoppable Growth Stock to Invest in Now?",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/J713X2G_4n.5dZjnwBOXZw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/7b0524267df57743748c8c566f6ab6ea.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3TpP6OHB5FXGiA99gusCDw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/7b0524267df57743748c8c566f6ab6ea.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/analysts-think-halozyme-therapeutics-halo-164149905.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/analysts-think-halozyme-therapeutics-halo-164149905.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HALO"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]